Allergan adopts poison pill against $48bn Valeant bid
This article was originally published in Scrip
Allergan adopted a stockholder rights plan, otherwise known as a poison pill, late on 22 April to protect its research pipeline and block a bid from Valeant Pharmaceuticals that values Allergan's Botox-led portfolio and late-stage development programs at $48bn.
You may also be interested in...
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.